To Mothers Struggling with Addiction: You Are Not Alone

I had an idyllic childhood. I was a cheery kid with great parents, raised in a wonderful neighborhood, always cared for and never wanted for anything. When people hear this background from someone whose addiction was so strong that they planned their methamphetamine use around their pregnancy, it can be hard to reconcile. There is no blueprint for addiction; this disease has no face. Not one person in my life would have guessed I’d be homeless with multiple DUIs, totaled a number of vehicles, and would have my son taken away by authorities twice before his second birthday, but it happened. And despite how absurd it may sound, having my son taken away from me is what saved my life.    At 14, I was a high school freshman dealing with weight issues, vicious bullying and low self-esteem. This experience left me with few friends, so when the group of cool kids invited me to a party, I went. That’s when my drinking started — leading eventually to other substances and behavioral issues. I barely graduated with my class, and even though I wanted to go to college, it didn’t happen. Instead, I spent my 20s trying any substance that came my way. Beginning in 2004, and for the next 10 years, I was in and out of treatment centers. I had periods of sobriety, but they never lasted long. During one stretch, I had a corporate job, bought a condo, and purchased a car. Everyone was thrilled for my new life. But on the inside, I was empty. None of the mater...
Source: Psych Central - Category: Psychiatry Authors: Tags: Addictions Parenting Substance Abuse Addiction Recovery custody Methamphetamines Motherhood Source Type: news

Related Links:

Publication date: Available online 3 July 2020Source: Saudi Journal of Biological SciencesAuthor(s): Shafat Ali, Sabhiya Majid, Md. Niamat Ali, Shahnaz Taing, Hamed A. El-Serehy, Fahad A. Al-Misned
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
Publication date: Available online 3 July 2020Source: Spatial and Spatio-temporal EpidemiologyAuthor(s): Felix Tran, Christopher Morrison
Source: Spatial and Spatio-temporal Epidemiology - Category: Epidemiology Source Type: research
Abstract Major depressive disorder is a prevalent and serious form of mental illness. While traditional antidepressants ameliorate some of the symptoms associated with depression, the onset of action typically takes several weeks leaving severely depressed individuals vulnerable to self-injurious behavior and possibly suicide. There has been a major unmet need for the development of pharmacological therapies that can quickly alleviate symptoms associated with depression. Clinical data shows that a single sub-psychomimetic dose of ketamine, a noncompetitive glutamatergic N-methyl-d-aspartate (NMDA) receptor antagon...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract Scopolamine is a nonselective muscarinic antagonist that has shown relatively rapid antidepressant effects, although to date the results are from limited clinical studies. Scopolamine reportedly has downstream signaling effects thought to be linked to neuroplasticity within glutamatergic synapses and consequent antidepressant action. In psychiatry, clinically validated pathways are unusual and thus merit further research in an effort develop more effect medicines for patients with mood disorders. Thus, we are faced with a unique opportunity to build on the clinical observation associated with scopolamine ...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract Conventional antidepressants typically require weeks of daily dosing to achieve full antidepressant response in antidepressant responders. A newly evolving group of compounds can engender more rapid response times in depressed patients. These drugs include the newly approved antidepressant (S)-ketamine (esketamine, Spravato). A seminal study by Furey and Drevets in 2006 showed antidepressant response in patients after only a few doses with the antimuscarinic drug scopolamine. Several clinical reports have generally confirmed scopolamine as a rapid-acting antidepressant. The data with scopolamine are consi...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract A single sub-anesthetic intravascular dose of the use-dependent NMDAR antagonist, ketamine, improves mood in patients with treatment resistant depression within hours that can last for days, creating an entirely new treatment strategy for the most seriously ill patients. However, the psychomimetic effects and abuse potential of ketamine require that new therapies be developed that maintain the rapid antidepressant effects of ketamine without the unwanted side effects. This necessitates a detailed understanding of what cellular and synaptic mechanisms are immediately activated once ketamine reaches the bra...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract Given that ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist that exerts rapid antidepressant effects in patients with treatment-resistant depression, also has undesirable adverse effects, agents that can be used as alternatives to ketamine have been actively pursued. Group II metabotropic glutamate (mGlu) receptors, consisting of mGlu2 and mGlu3 receptors, have emerged as one of the most promising targets in the development of ketamine-like antidepressants. Indeed, mGlu2/3 receptor antagonists have been demonstrated to exert rapid antidepressant effects in animal models and to be effica...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract A serious lack of effective pharmacotherapeutic interventions for posttraumatic stress disorder (PTSD) raises the urgent need for the development of novel treatments. Ketamine-a noncompetitive glutamate N-methyl-d-aspartate (NMDA) receptor antagonist in use for decades as an anesthetic and analgesic agent-has more recently been demonstrated to have rapid-onset antidepressant effects in patients with treatment-resistant depression (TRD). In the present review of ketamine as an emerging novel pharmacotherapeutic intervention for chronic PTSD, we discuss findings from the first proof-of-concept, randomized c...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract Major depressive disorder (MDD) is the leading cause of disability worldwide and reduces life expectancy. Achieving and sustaining remission from depression is challenging after initial improvement of an acute episode with an antidepressant, especially for patients whose depressive episodes have proven treatment-resistant in response to conventional antidepressant pharmacotherapy. While standard antidepressants are at least partly effective for the short-term treatment of acute depressive episodes of MDD, many patients relapse within 6 months of apparent clinical remission, with faster and higher rates ob...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
Abstract As a field, psychiatry is undergoing an exciting paradigm shift toward early identification and intervention that will likely minimize both the burden associated with severe mental illnesses as well as their duration. In this context, the rapid-acting antidepressant ketamine has revolutionized our understanding of antidepressant response and greatly expanded the pharmacologic armamentarium for treatment-resistant depression. Efforts to characterize biomarkers of ketamine response support a growing emphasis on early identification, which would allow clinicians to identify biologically enriched subgroups wi...
Source: Advances in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Adv Pharmacol Source Type: research
More News: Addiction | Brain | Child Abuse | Children | Cleft Palate | Depression | Graduation | Legislation | Men | Methamphetamine | Neurology | Overdose | Parenting | Pregnancy | Psychiatry | Reproduction Medicine | Substance Abuse | Substance Abuse Disorders | Suicide | Women